Brief: Sienna Biopharmaceuticals Reports Results from Study of SNA-125 In Psoriasis

Sienna Biopharmaceuticals

27/08/2018 14:16

Aug 27 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O :
    * SIENNA BIOPHARMACEUTICALS ANNOUNCES RESULTS FROM
FIRST-IN-HUMAN
STUDY OF SNA-125 IN PSORIASIS AND CONTINUED PROGRESSION TO PHASE
2
    * SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES
EXPECTED
TO BEGIN IN SECOND HALF OF 2019
    * SIENNA BIOPHARMACEUTICALS INC - SNA-125 PHASE 2 STUDIES
EXPECTED
TO BEGIN IN SECOND HALF OF 2019
    * SIENNA BIOPHARMACEUTICALS INC - PHASE 1/2 STUDY DATA OF
SNA-125
IN ATOPIC DERMATITIS ON TRACK TO BE RELEASED IN Q4 OF 2018
    * SIENNA BIOPHARMACEUTICALS - IN MODEL, SNA-125 WAS
WELL-TOLERATED
AND SHOWED NO SAFETY SIGNALS
    * SIENNA BIOPHARMA - IN MODEL, ANALYSES SHOWED MODEST,
STATISTICALLY SIGNIFICANT REDUCTION WITH SNA-125 0.2 PERCENT IN
EPIDERMAL THICKNESS FROM BASELINE

Source text for Eikon:  ID:nGNX56Gkwv 
Further company coverage:  SNNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))